Gofeld Michael, Smith Kevin J, Bhatia Anuj, Djuric Vladimir, Leblang Suzanne, Rebhun Niv, Aginsky Ron, Miller Eric, Skoglind Brian, Hananel Arik
Unika Medical Centre, Toronto, Ontario, Canada
Unika Medical Centre, Toronto, Ontario, Canada.
Reg Anesth Pain Med. 2025 Jun 10;50(6):464-470. doi: 10.1136/rapm-2024-105345.
The objective of this study is to investigate safety and effectiveness of a fluoroscopy-guided high-intensity focused ultrasound (HIFU) system for thermal ablation of the lumbar medial branch nerves.
This dual center prospective cohort study enrolled 30 participants with lumbar zygapophyseal joint syndrome. Each participant previously had a positive response to either a single diagnostic analgesic block or radiofrequency ablation (RFA). The primary effectiveness outcome was individual responder rate, defined as a reduction of two points or more on the pain intensity numerical rating scale without an increase in opioid intake, or a reduction in opioid intake without an increase in pain at 6 months after the intervention. The primary safety outcome was procedure-related or device-related adverse events (AEs). Secondary outcome variables included MRI evidence of tissue ablation, Oswestry Disability Index, 12-Item Short Form Health Survey, Brief Pain Inventory, and Patient Global Impression of Change.
The individual responder rate was 89.7% at 2 days, 89.7% at 7 days, 72.4% at 14 days, 82.1% at 30 days, 59.3% at 90 days and 82.6% at 180 days. The average Numeric Rating Scale for pain severity decreased from 7.1 at baseline to 3.0 (N=29) after 2 days, 3.0 (N=29) after 7 days, 3.1 (N=29) after 14 days, 3.2 (N=28) after 30 days, 4.3 (N=27) after 90 days, and 3.3 (N=23) after 180 days. All participants tolerated the procedure well with no significant side effects or complications.
Fluoroscopy-guided HIFU neurotomy achieved clinical responses comparable with RFA, and there were no significant device-related or procedure-related AEs.
NCT04129034.
本研究旨在探讨荧光透视引导下的高强度聚焦超声(HIFU)系统用于腰椎内侧支神经热消融的安全性和有效性。
这项双中心前瞻性队列研究纳入了30例腰椎小关节综合征患者。每位患者之前对单次诊断性镇痛阻滞或射频消融(RFA)均有阳性反应。主要有效性指标是个体反应率,定义为干预后6个月时疼痛强度数字评定量表降低2分或更多且阿片类药物摄入量未增加,或阿片类药物摄入量减少且疼痛未加重。主要安全性指标是与手术或设备相关的不良事件(AE)。次要结局变量包括组织消融的MRI证据、Oswestry功能障碍指数、12项简明健康调查、简短疼痛量表和患者总体变化印象。
个体反应率在2天时为89.7%,7天时为89.7%,14天时为72.4%,30天时为82.1%,90天时为59.3%,180天时为82.6%。疼痛严重程度的平均数字评定量表从基线时的7.1降至2天后的3.0(N = 29),7天后的3.0(N = 29),14天后的3.1(N = 29),30天后的3.2(N = 28),90天后的4.3(N = 27),180天后的3.3(N = 23)。所有患者对该手术耐受性良好,无明显副作用或并发症。
荧光透视引导下的HIFU神经切断术取得了与RFA相当的临床反应,且无明显的与设备或手术相关的不良事件。
NCT04129034。